TABLE 1.
The clinical characteristics of the subjects
| Control | CRSsNP | CRSwNP | p value | |
|---|---|---|---|---|
| N = 15 | N = 14 | N = 37 | ||
| Age (y) | 40.9 ± 12.6 | 44.4 ± 13.0 | 44.1 ± 13.4 | 0.695 |
| Male, n (%) | 8 (53.3) | 3 (21.4) | 9 (24.3) | 0.056 |
| Smoker, n (%) | 4 (26.7) | 3 (21.4) | 15 (40.5) | 0.357 |
| Asthma, n (%) | 0 (0) | 1 (7.1) | 4 (10.8) | 0.409 |
| Atopy, n (%) | 0 (0) | 4 (28.6) | 15 (40.5) | 0.014 a , b |
| AERD | 0/15 | 0/14 | 4/37 | 0.188 |
| Tissue Eos (number/HPF) | 0 (0–1) | 6.5 (0–30) | 45 (0–900) | 0.001 a , b , c |
| Tissue Neu(number/HPF) | 0 (0–5) | 0 (0–150) | 0 (0–5) | 0.754 |
| Blood Eos (%) | 1.6 (0.5–7.5) | 4.9 (2.3–7.8) | 4.8 (1–20.1) | 0.008 a , b |
| Blood Neu(%) | 51.3 (39.1–59.4) | 52.5 (40–60.5) | 54 (34.5–69.4) | 0.526 |
| LMS | 0 (0–2) | 6 (2–16) | 14 (2–24) | <0.001 a , b , c |
Note: Data are expressed as numbers (%), means ± standard deviation, or median (range). a, b, c were considered statistically significant (p < 0.05).
Abbreviations: AERD, aspirin‐exacerbated respiratory disease; Eos, eosinophil; HPF, high power field; LMS, Lund‐Mackay scoring system; Neu, neutrophil.
a
Control versus CRSsNP.
b
Control versus CRSwNP.
c
CRSsNP versus CRSwNP.